Evotec SE and Sandoz AG, a division of Novartis, announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars. The partnership includes an option for the non-exclusive in-licensing of Just – Evotec Biologics’ technology by Sandoz for building its fully-owned S.POD facility (in analogy to Just – Evotec Biologics’ state-of-the-art J...